e-learning
resources
European Respiratory Review
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Cottin Vincent
Source:
Eur Respir Rev 2012; 21: 161-167
Journal Issue:
June 2012 - 21 (124)
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Cottin Vincent. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir Rev 2012; 21: 161-167
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 52 (2) 1702593; 10.1183/13993003.02593-2017
Year: 2018
Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 39: 359-365
Year: 2012
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation
Source: Eur Respir J 2012; 40: 794-795
Year: 2012
Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis?
Source: Eur Respir J 2003 Dec 01;22(6):906-911
Year: 2003
The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points
Source: Eur Respir Rev 2011; 20: 195-200
Year: 2011
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
The effect of pulmonary rehabilitation on exercise tolerance pulmonary function dyspnea and quality of life in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema
Source: Eur Respir J 2011; 37: 176-183
Year: 2011
Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
Source: Eur Respir Rev 2011; 20: 201-207
Year: 2011
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Early decrease of forced vital capacity is a good prediction tool for prognosis in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept